Author(s):
Seftika Sari, Tri Murti Andayani, Dwi Endarti, Kartika Widayati
Email(s):
seftika1987.apt@gmail.com
DOI:
10.52711/0974-360X.2022.00267
Address:
Seftika Sari1*, Tri Murti Andayani2, Dwi Endarti3, Kartika Widayati4
1Sekolah Tinggi Ilmu Farmasi Riau, Pekanbaru, Indonesia.
2Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Gadjah Mada University, Yogyakarta, Indonesia.
3Department of Pharmaceutics, Faculty of Pharmacy, Gadjah Mada University, Yogyakarta, Indonesia.
4Department of Internal Medicine, Division of Hematology and Medical Oncology, Faculty of Medicine Gadjah Mada University - Dr. Sardjito Hospital, Yogyakarta, Indonesia.
*Corresponding Author
Published In:
Volume - 15,
Issue - 4,
Year - 2022
Cite this article:
Seftika Sari, Tri Murti Andayani, Dwi Endarti, Kartika Widayati. Cost-Effectiveness Analysis of Afatinib versus Gefitinib in Non-small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) Mutation in Indonesia: Observational studies with Retrospectives. Research Journal of Pharmacy and Technology. 2022; 15(4):1598-2. doi: 10.52711/0974-360X.2022.00267